-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
After collecting and "persuading" pseudo-innovations, two years later, the key monitoring catalogue officially nominated anti-tumor drugs
.
In recent years, the anti-tumor drug market has continued to expand.
In 2020, the terminal sales of public medical institutions in China will exceed 100 billion yuan
.
Among the TOP20 anti-tumor drugs, the sales of many PD-1 and tinib have soared, and the post-harvest market of old-brand products has been "halved"
.
A total of 17 types of anti-tumor drugs have been included in the centralized procurement, and the market has been or is facing shrinking
.
Among the 10 innovative anti-tumor drugs approved for marketing in China this year, PD-1 and tinib account for 6 of them
.
.
In recent years, the anti-tumor drug market has continued to expand.
In 2020, the terminal sales of public medical institutions in China will exceed 100 billion yuan
.
Among the TOP20 anti-tumor drugs, the sales of many PD-1 and tinib have soared, and the post-harvest market of old-brand products has been "halved"
.
A total of 17 types of anti-tumor drugs have been included in the centralized procurement, and the market has been or is facing shrinking
.
Among the 10 innovative anti-tumor drugs approved for marketing in China this year, PD-1 and tinib account for 6 of them
.
The market breaks through hundreds of billions! The anti-tumor drug TOP20 has obvious ups and downs
Anti-tumor drugs and systemic anti-bacterial drugs are the most widely used categories of clinical drugs in China
.
The difference is that systemic antibacterial drugs have experienced a sharp decline in sales under the impact of a series of policies such as transfer restriction, resistance restriction and centralized procurement, while antitumor drugs are used in new products such as PD-1, tinib drugs, and biosimilars.
Stimulated by the stimulus, the market scale reached a new high
.
.
The difference is that systemic antibacterial drugs have experienced a sharp decline in sales under the impact of a series of policies such as transfer restriction, resistance restriction and centralized procurement, while antitumor drugs are used in new products such as PD-1, tinib drugs, and biosimilars.
Stimulated by the stimulus, the market scale reached a new high
.
Meters within the network data show that in 2020 China's urban public hospitals , county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) terminal anti -tumor drug sales exceeded 100 billion yuan, an increase of 9.
63%
.
63%
.
Sales of terminal anti-tumor drugs in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Among the TOP20 anti-tumor drugs, 20 varieties have sales of more than 1 billion yuan.
Roche’s trastuzumab ranks first with sales of more than 5 billion yuan.
There are 5 varieties of monoclonal antibodies and tinib drugs each.
List
.
Roche’s trastuzumab ranks first with sales of more than 5 billion yuan.
There are 5 varieties of monoclonal antibodies and tinib drugs each.
List
.
Top 20 Terminal Anti-tumor Drugs in China's Public Medical Institutions
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
In terms of sales growth rate, Cinda's Sintilizumab and Hengrui's Carrelizumab increased by 545.
69% and 491.
21% respectively
.
AstraZeneca’s osimertinib and CP Tianqing’s anlotinib also performed well, both increasing by more than 60%
.
Bevacizumab also achieved an increase of nearly 35% under the "assistance" of Qilu Pharmaceutical's biosimilar drugs
.
69% and 491.
21% respectively
.
AstraZeneca’s osimertinib and CP Tianqing’s anlotinib also performed well, both increasing by more than 60%
.
Bevacizumab also achieved an increase of nearly 35% under the "assistance" of Qilu Pharmaceutical's biosimilar drugs
.
At the time when innovative drugs such as PD-1 and tinib drugs are "exploiting territory", the former star products are slightly lonely
.
.
Half of the anti-tumor drug sales in the TOP20 declined
.
Sales of Tiggio capsules fell by more than 50%, paclitaxel liposomes fell by more than 20%, and pemetrexed, imatinib, and docetaxel fell by more than 10%
.
It is not difficult to find that most of these varieties have been included in the national collection
.
.
Sales of Tiggio capsules fell by more than 50%, paclitaxel liposomes fell by more than 20%, and pemetrexed, imatinib, and docetaxel fell by more than 10%
.
It is not difficult to find that most of these varieties have been included in the national collection
.
10 Class 1 anti-tumor drugs approved! PD-1 and tinib drugs get together
Protein kinase inhibitors (tinib drugs) and monoclonal antibodies are the strongest growth sub-categories in the anti-tumor drug market.
In 2020, the terminal sales growth rate of public medical institutions in China will be 29.
79% and 40.
94%, respectively
.
In 2020, the terminal sales growth rate of public medical institutions in China will be 29.
79% and 40.
94%, respectively
.
At present, whether it is a leading pharmaceutical company or a small pharmaceutical company, most of them are betting on the research and development of anti-tumor drugs, especially PD-1 and tinib drugs
.
.
According to data from Minai.
com, there are a total of 10 Class 1 anti-tumor innovative drugs approved for marketing for the first time in China since 2021, of which 7 are tinib drugs and monoclonal antibodies
.
com, there are a total of 10 Class 1 anti-tumor innovative drugs approved for marketing for the first time in China since 2021, of which 7 are tinib drugs and monoclonal antibodies
.
Imatinib has 4 drugs, including Ellis US volts mesylate tablets imatinib, imatinib Playa cornerstone of medicine capsules, and yellow pharmaceutical tournament fertile imatinib Jing Ze pharmaceutical tablets and multi-toluenesulfonic acid Nafenib tablets
.
It is worth noting that there are still 6 domestic pharmaceutical companies whose applications for new class 1 protein kinase inhibitor drugs are under review, including Qilu Pharmaceuticals, Hengrui Pharmaceuticals, Betta Pharmaceuticals, and Aisen Biotech
.
.
It is worth noting that there are still 6 domestic pharmaceutical companies whose applications for new class 1 protein kinase inhibitor drugs are under review, including Qilu Pharmaceuticals, Hengrui Pharmaceuticals, Betta Pharmaceuticals, and Aisen Biotech
.
Local companies whose applications for protein kinase inhibitors are under review
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
There are 2 types of PD-1 monoclonal antibodies, specifically Kangfang Biologics Paimrizumab injection and Yuheng Biologics Sepalizumab injection
.
At present, 6 domestically produced PD-1 monoclonal antibodies have been approved for listing in the domestic market, and 3 PD-1 monoclonal antibodies are under review, including Genolizumab from Jiahe Biologics and Slulimumab from Henlius.
And Lepu Bio's Pratrizumab
.
.
At present, 6 domestically produced PD-1 monoclonal antibodies have been approved for listing in the domestic market, and 3 PD-1 monoclonal antibodies are under review, including Genolizumab from Jiahe Biologics and Slulimumab from Henlius.
And Lepu Bio's Pratrizumab
.
17 varieties have been collected, new anti-cancer drug regulations, key monitoring and heavy punching
In the five batches and six rounds of centralized collections carried out by the country, systemic antibacterial drugs, antitumor drugs, diabetes drugs, drugs that act on the renin-angiotensin system, anti-inflammatory drugs and antirheumatic drugs are the main subjects for inclusion.
A total of 17 types of oncology drugs have been included in the collection, and the market for these types has been or is facing shrinking
.
A total of 17 types of oncology drugs have been included in the collection, and the market for these types has been or is facing shrinking
.
Gefitinib, imatinib and pemetrexed are the first batch of collectively collected varieties, and terminal sales in China's public medical institutions will all experience a sharp decline in 2020
.
The peak sales of gefitinib and imatinib were in 2018.
After pemetrexed sales increased by 3.
12% in 2019 and exceeded 5 billion yuan, sales in 2020 fell by 17.
54%
.
.
The peak sales of gefitinib and imatinib were in 2018.
After pemetrexed sales increased by 3.
12% in 2019 and exceeded 5 billion yuan, sales in 2020 fell by 17.
54%
.
National centralized procurement of anti-tumor drugs
After the old-brand anti-tumor varieties were basically included in the centralized procurement, anti-tumor innovative drugs began to become the new "sniper" targets for medical insurance control fees
.
.
On July 2, the Center for Drug Evaluation (CDE) of the State Food and Drug Administration issued the "Clinical Value-Oriented Anti-tumor Drug Clinical Development Guidelines (Draft for Comment)", emphasizing that drug development should be based on patient needs and clinical Value-oriented, encourage flexible and efficient clinical design, and encourage accelerated listing
.
.
The impact of the new regulations on pseudo-innovation has led to a collective collapse of pharmaceutical stocks, and its power can be seen
.
But the positive is that the file is a kind of domestic research and development of anticancer drugs correction, avoid companies get together >
.
.
But the positive is that the file is a kind of domestic research and development of anticancer drugs correction, avoid companies get together >
.
After collecting and "persuading" pseudo-innovations, two years later, the key monitoring catalogue officially nominated anti-tumor drugs
.
.
In June 2019, the National Health Commission released the "First Batch of National Key Monitoring Drugs for Reasonable Use (Chemical and Biological Products)", with 20 varieties on the list, with neurological drugs and cardiovascular drugs bearing the brunt of the list, and anti-tumor drugs Then unscathed
.
.
On September 3, 2021, the National Health Commission officially issued the "Notice on the Regulations for the Adjustment of the National Key Monitoring and Rational Use Drug List"
.
The "Notice" stated that the time for catalog update and adjustment should not be less than 3 years in principle, and the number of drug varieties included in catalog management is generally 30; the focus is on monitoring unreasonable clinical use, many problems, abnormally high usage amount, and rationality of drug use.
greater impact chemicals and biological products; key comprising adjunct, antineoplastic agents, antimicrobials, proton pump inhibitors, glucocorticoids, parenteral nutrition drugs
.
.
The "Notice" stated that the time for catalog update and adjustment should not be less than 3 years in principle, and the number of drug varieties included in catalog management is generally 30; the focus is on monitoring unreasonable clinical use, many problems, abnormally high usage amount, and rationality of drug use.
greater impact chemicals and biological products; key comprising adjunct, antineoplastic agents, antimicrobials, proton pump inhibitors, glucocorticoids, parenteral nutrition drugs
.
Centralized procurement, key monitoring, and guidelines for clinical research and development of anti-cancer drugs are all policies at the national level, and anti-cancer drugs are also active at the local level
.
For example, on July 28, the Guangdong Pharmaceutical Association issued the "Guiding Opinions on the Classification and Management of Anti-tumor Drugs in Medical Institutions of Guangdong Province", which included 78 anti-tumor drugs into the ranks of restricted drugs
.
.
For example, on July 28, the Guangdong Pharmaceutical Association issued the "Guiding Opinions on the Classification and Management of Anti-tumor Drugs in Medical Institutions of Guangdong Province", which included 78 anti-tumor drugs into the ranks of restricted drugs
.
When all companies are innovating, differentiated, high-quality innovation becomes a new demand
.
It's time to cool down the craze for anti-tumor innovative drug research and development!
.
It's time to cool down the craze for anti-tumor innovative drug research and development!
After collecting and "persuading" pseudo-innovations, two years later, the key monitoring catalogue officially nominated anti-tumor drugs
.
In recent years, the anti-tumor drug market has continued to expand.
In 2020, the terminal sales of public medical institutions in China will exceed 100 billion yuan
.
Among the TOP20 anti-tumor drugs, the sales of many PD-1 and tinib have soared, and the post-harvest market of old-brand products has been "halved"
.
A total of 17 types of anti-tumor drugs have been included in the centralized procurement, and the market has been or is facing shrinking
.
Among the 10 innovative anti-tumor drugs approved for marketing in China this year, PD-1 and tinib account for 6 of them
.
.
In recent years, the anti-tumor drug market has continued to expand.
In 2020, the terminal sales of public medical institutions in China will exceed 100 billion yuan
.
Among the TOP20 anti-tumor drugs, the sales of many PD-1 and tinib have soared, and the post-harvest market of old-brand products has been "halved"
.
A total of 17 types of anti-tumor drugs have been included in the centralized procurement, and the market has been or is facing shrinking
.
Among the 10 innovative anti-tumor drugs approved for marketing in China this year, PD-1 and tinib account for 6 of them
.
The market breaks through hundreds of billions! The anti-tumor drug TOP20 has obvious ups and downs
Anti-tumor drugs and systemic anti-bacterial drugs are the most widely used categories of clinical drugs in China
.
The difference is that systemic antibacterial drugs have experienced a sharp decline in sales under the impact of a series of policies such as transfer restriction, resistance restriction and centralized procurement, while antitumor drugs are used in new products such as PD-1, tinib drugs, and biosimilars.
Stimulated by the stimulus, the market scale reached a new high
.
.
The difference is that systemic antibacterial drugs have experienced a sharp decline in sales under the impact of a series of policies such as transfer restriction, resistance restriction and centralized procurement, while antitumor drugs are used in new products such as PD-1, tinib drugs, and biosimilars.
Stimulated by the stimulus, the market scale reached a new high
.
Meters within the network data show that in 2020 China's urban public hospitals , county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) terminal anti -tumor drug sales exceeded 100 billion yuan, an increase of 9.
63%
.
63%
.
Sales of terminal anti-tumor drugs in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Among the TOP20 anti-tumor drugs, 20 varieties have sales of more than 1 billion yuan.
Roche’s trastuzumab ranks first with sales of more than 5 billion yuan.
There are 5 varieties of monoclonal antibodies and tinib drugs each.
List
.
Roche’s trastuzumab ranks first with sales of more than 5 billion yuan.
There are 5 varieties of monoclonal antibodies and tinib drugs each.
List
.
Top 20 Terminal Anti-tumor Drugs in China's Public Medical Institutions
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
In terms of sales growth rate, Cinda's Sintilizumab and Hengrui's Carrelizumab increased by 545.
69% and 491.
21% respectively
.
AstraZeneca’s osimertinib and CP Tianqing’s anlotinib also performed well, both increasing by more than 60%
.
Bevacizumab also achieved an increase of nearly 35% under the "assistance" of Qilu Pharmaceutical's biosimilar drugs
.
69% and 491.
21% respectively
.
AstraZeneca’s osimertinib and CP Tianqing’s anlotinib also performed well, both increasing by more than 60%
.
Bevacizumab also achieved an increase of nearly 35% under the "assistance" of Qilu Pharmaceutical's biosimilar drugs
.
At the time when innovative drugs such as PD-1 and tinib drugs are "exploiting territory", the former star products are slightly lonely
.
.
Half of the anti-tumor drug sales in the TOP20 declined
.
Sales of Tiggio capsules fell by more than 50%, paclitaxel liposomes fell by more than 20%, and pemetrexed, imatinib, and docetaxel fell by more than 10%
.
It is not difficult to find that most of these varieties have been included in the national collection
.
.
Sales of Tiggio capsules fell by more than 50%, paclitaxel liposomes fell by more than 20%, and pemetrexed, imatinib, and docetaxel fell by more than 10%
.
It is not difficult to find that most of these varieties have been included in the national collection
.
10 Class 1 anti-tumor drugs approved! PD-1 and tinib drugs get together
Protein kinase inhibitors (tinib drugs) and monoclonal antibodies are the strongest growth sub-categories in the anti-tumor drug market.
In 2020, the terminal sales growth rate of public medical institutions in China will be 29.
79% and 40.
94%, respectively
.
In 2020, the terminal sales growth rate of public medical institutions in China will be 29.
79% and 40.
94%, respectively
.
At present, whether it is a leading pharmaceutical company or a small pharmaceutical company, most of them are betting on the research and development of anti-tumor drugs, especially PD-1 and tinib drugs
.
.
According to data from Minai.
com, there are a total of 10 Class 1 anti-tumor innovative drugs approved for marketing for the first time in China since 2021, of which 7 are tinib drugs and monoclonal antibodies
.
com, there are a total of 10 Class 1 anti-tumor innovative drugs approved for marketing for the first time in China since 2021, of which 7 are tinib drugs and monoclonal antibodies
.
Imatinib has 4 drugs, including Ellis US volts mesylate tablets imatinib, imatinib Playa cornerstone of medicine capsules, and yellow pharmaceutical tournament fertile imatinib Jing Ze pharmaceutical tablets and multi-toluenesulfonic acid Nafenib tablets
.
It is worth noting that there are still 6 domestic pharmaceutical companies whose applications for new class 1 protein kinase inhibitor drugs are under review, including Qilu Pharmaceuticals, Hengrui Pharmaceuticals, Betta Pharmaceuticals, and Aisen Biotech
.
.
It is worth noting that there are still 6 domestic pharmaceutical companies whose applications for new class 1 protein kinase inhibitor drugs are under review, including Qilu Pharmaceuticals, Hengrui Pharmaceuticals, Betta Pharmaceuticals, and Aisen Biotech
.
Local companies whose applications for protein kinase inhibitors are under review
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
There are 2 types of PD-1 monoclonal antibodies, specifically Kangfang Biologics Paimrizumab injection and Yuheng Biologics Sepalizumab injection
.
At present, 6 domestically produced PD-1 monoclonal antibodies have been approved for listing in the domestic market, and 3 PD-1 monoclonal antibodies are under review, including Genolizumab from Jiahe Biologics and Slulimumab from Henlius.
And Lepu Bio's Pratrizumab
.
.
At present, 6 domestically produced PD-1 monoclonal antibodies have been approved for listing in the domestic market, and 3 PD-1 monoclonal antibodies are under review, including Genolizumab from Jiahe Biologics and Slulimumab from Henlius.
And Lepu Bio's Pratrizumab
.
17 varieties have been collected, new anti-cancer drug regulations, key monitoring and heavy punching
In the five batches and six rounds of centralized collections carried out by the country, systemic antibacterial drugs, antitumor drugs, diabetes drugs, drugs that act on the renin-angiotensin system, anti-inflammatory drugs and antirheumatic drugs are the main subjects for inclusion.
A total of 17 types of oncology drugs have been included in the collection, and the market for these types has been or is facing shrinking
.
A total of 17 types of oncology drugs have been included in the collection, and the market for these types has been or is facing shrinking
.
Gefitinib, imatinib and pemetrexed are the first batch of collectively collected varieties, and terminal sales in China's public medical institutions will all experience a sharp decline in 2020
.
The peak sales of gefitinib and imatinib were in 2018.
After pemetrexed sales increased by 3.
12% in 2019 and exceeded 5 billion yuan, sales in 2020 fell by 17.
54%
.
.
The peak sales of gefitinib and imatinib were in 2018.
After pemetrexed sales increased by 3.
12% in 2019 and exceeded 5 billion yuan, sales in 2020 fell by 17.
54%
.
National centralized procurement of anti-tumor drugs
After the old-brand anti-tumor varieties were basically included in the centralized procurement, anti-tumor innovative drugs began to become the new "sniper" targets for medical insurance control fees
.
.
On July 2, the Center for Drug Evaluation (CDE) of the State Food and Drug Administration issued the "Clinical Value-Oriented Anti-tumor Drug Clinical Development Guidelines (Draft for Comment)", emphasizing that drug development should be based on patient needs and clinical Value-oriented, encourage flexible and efficient clinical design, and encourage accelerated listing
.
.
The impact of the new regulations on pseudo-innovation has led to a collective collapse of pharmaceutical stocks, and its power can be seen
.
But the positive is that the file is a kind of domestic research and development of anticancer drugs correction, avoid companies get together >
.
.
But the positive is that the file is a kind of domestic research and development of anticancer drugs correction, avoid companies get together >
.
After collecting and "persuading" pseudo-innovations, two years later, the key monitoring catalogue officially nominated anti-tumor drugs
.
.
In June 2019, the National Health Commission released the "First Batch of National Key Monitoring Drugs for Reasonable Use (Chemical and Biological Products)", with 20 varieties on the list, with neurological drugs and cardiovascular drugs bearing the brunt of the list, and anti-tumor drugs Then unscathed
.
.
On September 3, 2021, the National Health Commission officially issued the "Notice on the Regulations for the Adjustment of the National Key Monitoring and Rational Use Drug List"
.
The "Notice" stated that the time for catalog update and adjustment should not be less than 3 years in principle, and the number of drug varieties included in catalog management is generally 30; the focus is on monitoring unreasonable clinical use, many problems, abnormally high usage amount, and rationality of drug use.
greater impact chemicals and biological products; key comprising adjunct, antineoplastic agents, antimicrobials, proton pump inhibitors, glucocorticoids, parenteral nutrition drugs
.
.
The "Notice" stated that the time for catalog update and adjustment should not be less than 3 years in principle, and the number of drug varieties included in catalog management is generally 30; the focus is on monitoring unreasonable clinical use, many problems, abnormally high usage amount, and rationality of drug use.
greater impact chemicals and biological products; key comprising adjunct, antineoplastic agents, antimicrobials, proton pump inhibitors, glucocorticoids, parenteral nutrition drugs
.
Centralized procurement, key monitoring, and guidelines for clinical research and development of anti-cancer drugs are all policies at the national level, and anti-cancer drugs are also active at the local level
.
For example, on July 28, the Guangdong Pharmaceutical Association issued the "Guiding Opinions on the Classification and Management of Anti-tumor Drugs in Medical Institutions of Guangdong Province", which included 78 anti-tumor drugs into the ranks of restricted drugs
.
.
For example, on July 28, the Guangdong Pharmaceutical Association issued the "Guiding Opinions on the Classification and Management of Anti-tumor Drugs in Medical Institutions of Guangdong Province", which included 78 anti-tumor drugs into the ranks of restricted drugs
.
When all companies are innovating, differentiated, high-quality innovation becomes a new demand
.
It's time to cool down the craze for anti-tumor innovative drug research and development!
.
It's time to cool down the craze for anti-tumor innovative drug research and development!
After collecting and "persuading" pseudo-innovations, two years later, the key monitoring catalogue officially nominated anti-tumor drugs
.
In recent years, the anti-tumor drug market has continued to expand.
In 2020, the terminal sales of public medical institutions in China will exceed 100 billion yuan
.
Among the TOP20 anti-tumor drugs, the sales of many PD-1 and tinib have soared, and the post-harvest market of old-brand products has been "halved"
.
A total of 17 types of anti-tumor drugs have been included in the centralized procurement, and the market has been or is facing shrinking
.
Among the 10 innovative anti-tumor drugs approved for marketing in China this year, PD-1 and tinib account for 6 of them
.
.
In recent years, the anti-tumor drug market has continued to expand.
In 2020, the terminal sales of public medical institutions in China will exceed 100 billion yuan
.
Among the TOP20 anti-tumor drugs, the sales of many PD-1 and tinib have soared, and the post-harvest market of old-brand products has been "halved"
.
A total of 17 types of anti-tumor drugs have been included in the centralized procurement, and the market has been or is facing shrinking
.
Among the 10 innovative anti-tumor drugs approved for marketing in China this year, PD-1 and tinib account for 6 of them
.
The market breaks through hundreds of billions! The anti-tumor drug TOP20 has obvious ups and downs
The market breaks through hundreds of billions! The anti-tumor drug TOP20 has obvious ups and downs Anti-tumor drugs and systemic anti-bacterial drugs are the most widely used categories of clinical drugs in China
.
The difference is that systemic antibacterial drugs have experienced a sharp decline in sales under the impact of a series of policies such as transfer restriction, resistance restriction and centralized procurement, while antitumor drugs are used in new products such as PD-1, tinib drugs, and biosimilars.
Stimulated by the stimulus, the market scale reached a new high
.
.
The difference is that systemic antibacterial drugs have experienced a sharp decline in sales under the impact of a series of policies such as transfer restriction, resistance restriction and centralized procurement, while antitumor drugs are used in new products such as PD-1, tinib drugs, and biosimilars.
Stimulated by the stimulus, the market scale reached a new high
.
Meters within the network data show that in 2020 China's urban public hospitals , county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) terminal anti -tumor drug sales exceeded 100 billion yuan, an increase of 9.
63%
.
Hospital hospital hospital tumor tumor tumor63%
.
Sales of terminal anti-tumor drugs in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Among the TOP20 anti-tumor drugs, 20 varieties have sales of more than 1 billion yuan.
Roche’s trastuzumab ranks first with sales of more than 5 billion yuan.
There are 5 varieties of monoclonal antibodies and tinib drugs each.
List
.
Roche’s trastuzumab ranks first with sales of more than 5 billion yuan.
There are 5 varieties of monoclonal antibodies and tinib drugs each.
List
.
Top 20 Terminal Anti-tumor Drugs in China's Public Medical Institutions
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
In terms of sales growth rate, Cinda's Sintilizumab and Hengrui's Carrelizumab increased by 545.
69% and 491.
21% respectively
.
AstraZeneca’s osimertinib and CP Tianqing’s anlotinib also performed well, both increasing by more than 60%
.
Bevacizumab also achieved an increase of nearly 35% under the "assistance" of Qilu Pharmaceutical's biosimilar drugs
.
69% and 491.
21% respectively
.
AstraZeneca’s osimertinib and CP Tianqing’s anlotinib also performed well, both increasing by more than 60%
.
Bevacizumab also achieved an increase of nearly 35% under the "assistance" of Qilu Pharmaceutical's biosimilar drugs
.
At the time when innovative drugs such as PD-1 and tinib drugs are "exploiting territory", the former star products are slightly lonely
.
.
Half of the anti-tumor drug sales in the TOP20 declined
.
Sales of Tiggio capsules fell by more than 50%, paclitaxel liposomes fell by more than 20%, and pemetrexed, imatinib, and docetaxel fell by more than 10%
.
It is not difficult to find that most of these varieties have been included in the national collection
.
.
Sales of Tiggio capsules fell by more than 50%, paclitaxel liposomes fell by more than 20%, and pemetrexed, imatinib, and docetaxel fell by more than 10%
.
It is not difficult to find that most of these varieties have been included in the national collection
.
10 Class 1 anti-tumor drugs approved! PD-1 and tinib drugs get together
10 Class 1 anti-tumor drugs approved! PD-1 and tinib drugs get together Protein kinase inhibitors (tinib drugs) and monoclonal antibodies are the strongest growth sub-categories in the anti-tumor drug market.
In 2020, the terminal sales growth rate of public medical institutions in China will be 29.
79% and 40.
94%, respectively
.
In 2020, the terminal sales growth rate of public medical institutions in China will be 29.
79% and 40.
94%, respectively
.
At present, whether it is a leading pharmaceutical company or a small pharmaceutical company, most of them are betting on the research and development of anti-tumor drugs, especially PD-1 and tinib drugs
.
.
According to data from Minai.
com, there are a total of 10 Class 1 anti-tumor innovative drugs approved for marketing for the first time in China since 2021, of which 7 are tinib drugs and monoclonal antibodies
.
com, there are a total of 10 Class 1 anti-tumor innovative drugs approved for marketing for the first time in China since 2021, of which 7 are tinib drugs and monoclonal antibodies
.
Imatinib has 4 drugs, including Ellis US volts mesylate tablets imatinib, imatinib Playa cornerstone of medicine capsules, and yellow pharmaceutical tournament fertile imatinib Jing Ze pharmaceutical tablets and multi-toluenesulfonic acid Nafenib tablets
.
It is worth noting that there are still 6 domestic pharmaceutical companies whose applications for new class 1 protein kinase inhibitor drugs are under review, including Qilu Pharmaceuticals, Hengrui Pharmaceuticals, Betta Pharmaceuticals, and Aisen Biotech
.
Medicine Medicine Medicine.
It is worth noting that there are still 6 domestic pharmaceutical companies whose applications for new class 1 protein kinase inhibitor drugs are under review, including Qilu Pharmaceuticals, Hengrui Pharmaceuticals, Betta Pharmaceuticals, and Aisen Biotech
.
Local companies whose applications for protein kinase inhibitors are under review
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
There are 2 types of PD-1 monoclonal antibodies, specifically Kangfang Biologics Paimrizumab injection and Yuheng Biologics Sepalizumab injection
.
At present, 6 domestically produced PD-1 monoclonal antibodies have been approved for listing in the domestic market, and 3 PD-1 monoclonal antibodies are under review, including Genolizumab from Jiahe Biologics and Slulimumab from Henlius.
And Lepu Bio's Pratrizumab
.
.
At present, 6 domestically produced PD-1 monoclonal antibodies have been approved for listing in the domestic market, and 3 PD-1 monoclonal antibodies are under review, including Genolizumab from Jiahe Biologics and Slulimumab from Henlius.
And Lepu Bio's Pratrizumab
.
17 varieties have been collected, new anti-cancer drug regulations, key monitoring and heavy punching
17 varieties have been collected, new anti-cancer drug regulations, key monitoring and heavy punching In the five batches and six rounds of centralized collections carried out by the country, systemic antibacterial drugs, antitumor drugs, diabetes drugs, drugs that act on the renin-angiotensin system, anti-inflammatory drugs and antirheumatic drugs are the main subjects for inclusion.
A total of 17 types of oncology drugs have been included in the collection, and the market for these types has been or is facing shrinking
.
A total of 17 types of oncology drugs have been included in the collection, and the market for these types has been or is facing shrinking
.
Gefitinib, imatinib and pemetrexed are the first batch of collectively collected varieties, and terminal sales in China's public medical institutions will all experience a sharp decline in 2020
.
The peak sales of gefitinib and imatinib were in 2018.
After pemetrexed sales increased by 3.
12% in 2019 and exceeded 5 billion yuan, sales in 2020 fell by 17.
54%
.
.
The peak sales of gefitinib and imatinib were in 2018.
After pemetrexed sales increased by 3.
12% in 2019 and exceeded 5 billion yuan, sales in 2020 fell by 17.
54%
.
National centralized procurement of anti-tumor drugs
After the old-brand anti-tumor varieties were basically included in the centralized procurement, anti-tumor innovative drugs began to become the new "sniper" targets for medical insurance control fees
.
.
On July 2, the Center for Drug Evaluation (CDE) of the State Food and Drug Administration issued the "Clinical Value-Oriented Anti-tumor Drug Clinical Development Guidelines (Draft for Comment)", emphasizing that drug development should be based on patient needs and clinical Value-oriented, encourage flexible and efficient clinical design, and encourage accelerated listing
.
.
The impact of the new regulations on pseudo-innovation has led to a collective collapse of pharmaceutical stocks, and its power can be seen
.
But the positive is that the file is a kind of domestic research and development of anticancer drugs correction, avoid companies get together >
.
Enterprise business enterprise.
But the positive is that the file is a kind of domestic research and development of anticancer drugs correction, avoid companies get together >
.
After collecting and "persuading" pseudo-innovations, two years later, the key monitoring catalogue officially nominated anti-tumor drugs
.
.
In June 2019, the National Health Commission released the "First Batch of National Key Monitoring Drugs for Reasonable Use (Chemical and Biological Products)", with 20 varieties on the list, with neurological drugs and cardiovascular drugs bearing the brunt of the list, and anti-tumor drugs Then unscathed
.
Medicine, medicine, medicine.
On September 3, 2021, the National Health Commission officially issued the "Notice on the Regulations for the Adjustment of the National Key Monitoring and Rational Use Drug List"
.
The "Notice" stated that the time for catalog update and adjustment should not be less than 3 years in principle, and the number of drug varieties included in catalog management is generally 30; the focus is on monitoring unreasonable clinical use, many problems, abnormally high usage amount, and rationality of drug use.
greater impact chemicals and biological products; key comprising adjunct, antineoplastic agents, antimicrobials, proton pump inhibitors, glucocorticoids, parenteral nutrition drugs
.
.
The "Notice" stated that the time for catalog update and adjustment should not be less than 3 years in principle, and the number of drug varieties included in catalog management is generally 30; the focus is on monitoring unreasonable clinical use, many problems, abnormally high usage amount, and rationality of drug use.
greater impact chemicals and biological products; key comprising adjunct, antineoplastic agents, antimicrobials, proton pump inhibitors, glucocorticoids, parenteral nutrition drugs
.
Centralized procurement, key monitoring, and guidelines for clinical research and development of anti-cancer drugs are all policies at the national level, and anti-cancer drugs are also active at the local level
.
For example, on July 28, the Guangdong Pharmaceutical Association issued the "Guiding Opinions on the Classification and Management of Anti-tumor Drugs in Medical Institutions of Guangdong Province", which included 78 anti-tumor drugs into the ranks of restricted drugs
.
.
For example, on July 28, the Guangdong Pharmaceutical Association issued the "Guiding Opinions on the Classification and Management of Anti-tumor Drugs in Medical Institutions of Guangdong Province", which included 78 anti-tumor drugs into the ranks of restricted drugs
.
When all companies are innovating, differentiated, high-quality innovation becomes a new demand
.
It's time to cool down the craze for anti-tumor innovative drug research and development!
.
It's time to cool down the craze for anti-tumor innovative drug research and development!
